JP2022507534A5 - - Google Patents

Info

Publication number
JP2022507534A5
JP2022507534A5 JP2021526562A JP2021526562A JP2022507534A5 JP 2022507534 A5 JP2022507534 A5 JP 2022507534A5 JP 2021526562 A JP2021526562 A JP 2021526562A JP 2021526562 A JP2021526562 A JP 2021526562A JP 2022507534 A5 JP2022507534 A5 JP 2022507534A5
Authority
JP
Japan
Prior art keywords
nucleic acid
acid molecule
molecule according
factor
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021526562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507534A (ja
JP7532360B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061808 external-priority patent/WO2020102723A1/en
Publication of JP2022507534A publication Critical patent/JP2022507534A/ja
Publication of JP2022507534A5 publication Critical patent/JP2022507534A5/ja
Application granted granted Critical
Publication of JP7532360B2 publication Critical patent/JP7532360B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021526562A 2018-11-16 2019-11-15 ウィルソン病を処置するための組成物および方法 Active JP7532360B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862768744P 2018-11-16 2018-11-16
US62/768,744 2018-11-16
PCT/US2019/061808 WO2020102723A1 (en) 2018-11-16 2019-11-15 Compositions and methods for treating wilson's disease

Publications (3)

Publication Number Publication Date
JP2022507534A JP2022507534A (ja) 2022-01-18
JP2022507534A5 true JP2022507534A5 (cg-RX-API-DMAC7.html) 2023-06-27
JP7532360B2 JP7532360B2 (ja) 2024-08-13

Family

ID=70731690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021526562A Active JP7532360B2 (ja) 2018-11-16 2019-11-15 ウィルソン病を処置するための組成物および方法

Country Status (7)

Country Link
US (1) US20210369870A1 (cg-RX-API-DMAC7.html)
EP (2) EP4257155A3 (cg-RX-API-DMAC7.html)
JP (1) JP7532360B2 (cg-RX-API-DMAC7.html)
CN (1) CN113302290A (cg-RX-API-DMAC7.html)
CA (1) CA3118936A1 (cg-RX-API-DMAC7.html)
TW (1) TW202039854A (cg-RX-API-DMAC7.html)
WO (1) WO2020102723A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102863181B1 (ko) 2016-12-30 2025-09-23 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 윌슨병을 치료하기 위한 유전자 치료
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
KR20210112339A (ko) 2019-01-04 2021-09-14 울트라제닉스 파마수티컬 인코포레이티드 윌슨병을 치료하기 위한 유전자 요법 구축물
WO2022208342A1 (en) * 2021-04-01 2022-10-06 Pfizer Inc. Pharmaceutical compositions containing adeno-associated viral vector
CN115216481A (zh) * 2021-04-21 2022-10-21 四川至善唯新生物科技有限公司 一种表达量提高的截短型atp7b基因及其应用
CN113699211A (zh) * 2021-07-20 2021-11-26 深圳市儿童医院 一种用于儿童威尔森氏症快速筛查的参数组合和试剂盒
JP2024534936A (ja) * 2021-09-07 2024-09-26 アレクシオン ファーマシューティカルズ, インコーポレイテッド 銅代謝関連疾患又は障害を治療する方法
TW202323528A (zh) * 2021-10-18 2023-06-16 美商邏輯生物療法公司 用於治療威爾森氏病之基因療法
JP2025533994A (ja) * 2022-10-11 2025-10-09 メイラグティーエックス ユーケー アイアイ リミティド Atp7b遺伝子療法
EP4677077A4 (en) * 2023-03-06 2026-07-29 Lingyi Biotech Co Ltd TRUNCATED ATP7B GENE AND ITS USAGE
JP2026508707A (ja) * 2023-03-22 2026-03-11 スカイライン、セラピューティクス、リミテッド ウィルソン病の遺伝子療法のための組換えaav
WO2025002226A1 (zh) * 2023-06-28 2025-01-02 迈威(上海)生物科技股份有限公司 编码atp7b的核酸、腺相关病毒载体及其在制备防治肝豆状核变性的药物中的应用
CN120882865A (zh) * 2023-07-28 2025-10-31 凌意(杭州)生物科技有限公司 用于治疗威尔逊病的多核苷酸
CN117757797B (zh) * 2023-09-25 2024-08-16 北京圭特细胞科技有限公司 一种编码人III型胶原蛋白α链的核酸及其应用
WO2025110984A1 (en) * 2023-11-21 2025-05-30 Hydrogene Therapeutics, Inc. Compositions and methods for treating wilson's disease
CN117947035A (zh) * 2024-03-25 2024-04-30 上海凌医生物科技有限公司 一种增强基因表达的启动子
CN121265551A (zh) * 2024-07-02 2026-01-06 苏州星核迪赛生物技术有限公司 一种靶向肝实质细胞的核酸递送载体及其应用
CN121319202B (zh) * 2025-12-15 2026-04-07 凌意(杭州)生物科技有限公司 Atp7b抗体及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
WO2001036620A2 (en) * 1999-11-16 2001-05-25 Genzyme Corporation Vectors and transgenies with regulatory elements for gene delivery to the liver
EP1103610A1 (en) 1999-11-26 2001-05-30 Introgene B.V. Production of vaccines from immortalised mammalian cell lines
FR2808803B1 (fr) 2000-05-11 2004-12-10 Agronomique Inst Nat Rech Cellules es modifiees et gene specifique de cellules es
FR2836924B1 (fr) 2002-03-08 2005-01-14 Vivalis Lignees de cellules aviaires utiles pour la production de substances d'interet
JP4559429B2 (ja) 2003-05-21 2010-10-06 ジェンザイム・コーポレーション 空キャプシドを実質的に含まない組換えaavビリオン調製物を生成するための方法
WO2005012877A2 (en) 2003-08-01 2005-02-10 Dna Twopointo Inc. Systems and methods for antibody engineering
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
JP5956331B2 (ja) 2009-06-16 2016-07-27 ジェンザイム・コーポレーション 組換えaavベクターの改良された精製方法
EP2665813A2 (en) 2011-01-21 2013-11-27 Aarhus Universitet Crystal structure of a type ib p-type atpase
WO2015121793A1 (en) * 2014-02-11 2015-08-20 Friedrich Miescher Institute For Biomedical Research Müller cell-specific promoter
CN107208105A (zh) * 2014-12-17 2017-09-26 基础应用医学研究基金会 用于治疗威尔森病的核酸构建体和基因治疗载体
US11118238B2 (en) * 2014-12-17 2021-09-14 Fundación Para La Investigación Mèdica Aplicada Nucleic acid constructs and gene therapy vectors for use in the treatment of Wilson's disease and other conditions
BR112017009835A2 (pt) * 2014-12-30 2017-12-26 Curevac Ag moléculas de ácido nucleico artificiais
JP6879486B2 (ja) * 2015-03-17 2021-06-02 フリーイェ・ユニヴェルシテイト・ブリュッセルVrije Universieit Brussel Fviiiおよびfix用の最適化された肝臓特異的発現系
GB201522416D0 (en) 2015-12-18 2016-02-03 Ucl Business Plc Wilson's disease gene therapy
KR102863181B1 (ko) * 2016-12-30 2025-09-23 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 윌슨병을 치료하기 위한 유전자 치료
US20210254056A1 (en) * 2017-05-05 2021-08-19 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks

Similar Documents

Publication Publication Date Title
JP2023076606A5 (cg-RX-API-DMAC7.html)
JP2021515548A5 (cg-RX-API-DMAC7.html)
JP7561788B2 (ja) 臨床使用に適した無血清懸濁細胞培養システムにおいて組換えアデノ随伴ウイルス(aav)ベクターを産生するスケーラブルな方法
JP2022530633A5 (cg-RX-API-DMAC7.html)
JP2022530656A5 (cg-RX-API-DMAC7.html)
JP2022530544A5 (cg-RX-API-DMAC7.html)
CN107864653B (zh) 衣壳
JP2023518919A (ja) Aavを産生する方法
RU2017125234A (ru) Конструкции нуклеиновой кислоты и векторы для генотерапии для применения для лечения болезни вильсона и других состояний
JP2022534809A5 (cg-RX-API-DMAC7.html)
JP2024514956A (ja) 組織標的化された改変aavカプシドおよびその使用方法
JP2020510429A5 (cg-RX-API-DMAC7.html)
JP2022549380A5 (cg-RX-API-DMAC7.html)
JP2017536116A5 (cg-RX-API-DMAC7.html)
JP7598333B2 (ja) 組換えウイルスベクターの製造方法
JP2014239686A5 (cg-RX-API-DMAC7.html)
JP2022529631A5 (cg-RX-API-DMAC7.html)
JP2018522529A5 (cg-RX-API-DMAC7.html)
JP2023537625A5 (cg-RX-API-DMAC7.html)
CA2682108A1 (en) Methods for generating high titer helper-free preparations of recombinant aav vectors
JP2024517104A5 (cg-RX-API-DMAC7.html)
JP2023550581A5 (cg-RX-API-DMAC7.html)
JP2022542828A5 (cg-RX-API-DMAC7.html)
AR123838A1 (es) Vector mejorado de virus adenoasociado (aav) y usos de este
JP2024542950A5 (cg-RX-API-DMAC7.html)